Filtered By:
Cancer: Bone Cancers

This page shows you your search results in order of date. This is page number 13.

Order by Relevance | Date

Total 366 results found since Jan 2013.

GSE73092 High-throughput RNAi cell viability screen to identify selective targets for EWS-FLI1 positive Ewing sarcoma
Contributors : Kristiina Iljin ; Tao HeSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensWe have performed a high-throughput RNA interference screen to identify targets inhibiting EWS-FLI1 driven cell proliferation in Ewing sarcoma cells. EWS-FLI1 expressing A673 Ewing sarcoma cells were screened both in presence and absence of EWS-FLI1 shRNA induction with druggable siRNA library. Leucine rich repeats and WD repeat Domain containing 1 (LRWD1) targeting siRNA pool was the strongest anti-proliferative hit identified only in presence of EWS-FLI1. Validation experiments confirmed the anti-...
Source: GEO: Gene Expression Omnibus - September 16, 2018 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research

Isoliquiritigenin inhibits mouse S180 tumors with a new mechanism that regulates autophagy by GSK-3 β/TNF-α pathway.
In this study, the pharmacokinetic properties and stability of isoliquiritigenin (ILQ) in microsomes were evaluated. The data showed ILQ administrated by i.h had high absorption degree (absolute bioavailability> 90%), and strong elimination ability (average t1/2≈ 67min). ILQ in rat tissues could reach peak at 0.25h, and be detected in almost all tissues. In vitro, stability of ILQ in four species liver microsomes were rat > beagle dog > monkey > human > mouse. On the basis of pharmacokinetic (PK) profiles, mechanism of ILQ against S180 was explored. ILQ could not inhibit S180 growth directly in vitro. Howe...
Source: European Journal of Pharmacology - August 29, 2018 Category: Drugs & Pharmacology Authors: Yushan R, Ying Y, Yujun T, Jingchun Y, Dongguang L, Lihong P, Pingping W, Lili Z, Fanhui Z, Zhong L, Guimin Z, Jie L Tags: Eur J Pharmacol Source Type: research

Long non-coding RNA NEAT1 promotes proliferation, migration and invasion of human osteosarcoma cells.
Conclusion: LncRNA NEAT1 was up-regulated in osteosarcoma tissue, promoting proliferation and metastasis of osteosarcoma cells. These findings indicate the role of this substance, as a growth regulator in osteosarcoma, and thus it may serve as a novel biomarker, and drug target for developing osteosarcoma therapies. PMID: 30123061 [PubMed - in process]
Source: International Journal of Medical Sciences - August 21, 2018 Category: Biomedical Science Tags: Int J Med Sci Source Type: research

The nuclear-cytoplasmic trafficking of a chromatin-modifying and remodelling protein (KMT2C), in osteosarcoma.
Authors: Chiappetta C, Puggioni C, Carletti R, Petrozza V, Della Rocca C, Di Crisfofano C Abstract Osteosarcoma is the most common paediatric primary non-hematopoietic bone tumor; the survival is related to the response to chemotherapy and development of metastases. KMT2C is a chromatin-modifying and remodelling protein and its expression has never been studied in osteosarcoma. The aim of this study was to understand the role of KMT2C in the osteosarcoma carcinogenesis and metastatic progression to identify a new molecular target and to provide new therapeutic approach. We performed the immunohistochemical and gene...
Source: Oncotarget - August 11, 2018 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

LncRNA THOR acts as a retinoblastoma promoter through enhancing the combination of c-myc mRNA and IGF2BP1 protein
In conclusion, this study makes clear that lncRNA THOR is up-regulated in retinoblastoma, and its over-expression significantly enhances the malignant phenotype transformation of retinoblastoma cells through up-regulating c-myc expression via enhancing its combination with TGF2BP1 protein. Overall, our study illustrates that lncRNA THOR/c-myc molecular cascade might be another potent target for retinoblastoma treatment.
Source: Biomedicine and Pharmacotherapy - July 20, 2018 Category: Drugs & Pharmacology Source Type: research

Theabrownin triggers DNA damage to suppress human osteosarcoma U2OS cells by activating p53 signalling pathway.
Abstract Osteosarcoma becomes the second leading cause of cancer death in the younger population. Current outcomes of chemotherapy on osteosarcoma were unsatisfactory to date, demanding development of effective therapies. Tea is a commonly used beverage beneficial to human health. As a major component of tea, theabrownin has been reported to possess anti-cancer activity. To evaluate its anti-osteosarcoma effect, we established a xenograft model of zebrafish and employed U2OS cells for in vivo and in vitro assays. The animal data showed that TB significantly inhibited the tumour growth with stronger effect than t...
Source: J Cell Mol Med - July 11, 2018 Category: Molecular Biology Authors: Jin W, Zhou L, Yan B, Yan L, Liu F, Tong P, Yu W, Dong X, Xie L, Zhang J, Xu Y, Li C, Yuan Q, Shan L, Efferth T Tags: J Cell Mol Med Source Type: research

Mannose-conjugated layered double hydroxide nanocomposite for targeted siRNA delivery to enhance cancer therapy
Publication date: Available online 22 June 2017Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Li Li, Run Zhang, Wenyi Gu, Zhi Ping XuAbstractSheet-like layered double hydroxide nanoparticles (LDH NPs) have showed great potentials in biomedical applications such as nanocarriers for drug and gene delivery, biosensors and imaging agents. However, target delivery of drugs and genes using LDH NPs to the desired tumor sites is a major challenge in cancer therapy. The aim of this study is to develop a functional LDH-based nanocomposite for target delivery of siRNA to cancer cells. Mannose as a targeting moie...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - July 10, 2018 Category: Nanotechnology Source Type: research

Silencing Ubc9 expression suppresses osteosarcoma tumorigenesis and enhances chemosensitivity to HSV-TK/GCV by regulating connexin  43 SUMOylation.
In conclusion, the present study revealed a novel method for the effective restoration of GJIC in osteosarcoma cells, which may increase their sensitivity to conventional chemotherapy. PMID: 29956745 [PubMed - as supplied by publisher]
Source: International Journal of Oncology - June 21, 2018 Category: Cancer & Oncology Authors: Zhang D, Yu K, Yang Z, Li Y, Ma X, Bian X, Liu F, Li L, Liu X, Wu W Tags: Int J Oncol Source Type: research

Activation of Sonic Hedgehog Signaling Is Associated with Human Osteosarcoma Cells Radioresistance Characterized by Increased Proliferation, Migration, and Invasion.
CONCLUSIONS Activation of Shh signaling was involved in radioresistance of OS cells. Blocking this signaling can impair the radioresistance capacity of OS cells. PMID: 29864766 [PubMed - in process]
Source: Medical Science Monitor - June 6, 2018 Category: Research Tags: Med Sci Monit Source Type: research

PYGB siRNA inhibits the cell proliferation of human osteosarcoma cell lines.
In conclusion, PYGB siRNA exerted an inhibitory effect on the cell viability of the human osteosarcoma cells MG63 and HOS by blocking the Caspase/Bcl and CDK1 signaling pathway, highlighting novel potential therapeutic methods for treating osteosarcoma. PMID: 29845265 [PubMed - as supplied by publisher]
Source: Molecular Medicine Reports - June 2, 2018 Category: Molecular Biology Tags: Mol Med Rep Source Type: research

Focal adhesion kinase promotes progression and predicts poor clinical outcomes in patients with osteosarcoma.
Authors: Gu HJ, Zhou B Abstract Osteosarcoma (OS) is a fatal form of musculoskeletal tumor that commonly leads to pulmonary metastatic disease. Traditional therapies such as surgery and chemotherapy are not effective treatment modalities in certain patients with OS; therefore, identifying the molecular mechanism of OS is imperative for the development of novel therapeutics. Previous studies have reported that focal adhesion kinase (FAK) is associated with numerous types of human malignancies. Therefore, in order to investigate the biological function of FAK in OS, the present study examined the expression levels of...
Source: Oncology Letters - June 1, 2018 Category: Cancer & Oncology Tags: Oncol Lett Source Type: research

Raddeanin A, a natural triterpenoid saponin compound, exerts anticancer effect on human osteosarcoma via the ROS/JNK and NF- κB signal pathway.
Raddeanin A, a natural triterpenoid saponin compound, exerts anticancer effect on human osteosarcoma via the ROS/JNK and NF-κB signal pathway. Toxicol Appl Pharmacol. 2018 May 27;: Authors: Ma B, Zhu J, Zhao A, Zhang J, Wang Y, Zhang H, Zhang L, Zhang Q Abstract Osteosarcoma (OS) is the most frequent and high mortality primary bone tumor in the adolescent. And it is well-known for poor prognosis due to high incidence of metastasis. Raddeanin A (RA), an active component of Anemone raddeana Regel, showed potential anti-cancer activities. However, the anti-tumor effect and molecular mechanism(s) of RA o...
Source: Toxicology and Applied Pharmacology - May 27, 2018 Category: Toxicology Authors: Ma B, Zhu J, Zhao A, Zhang J, Wang Y, Zhang H, Zhang L, Zhang Q Tags: Toxicol Appl Pharmacol Source Type: research

GPNMB silencing suppresses the proliferation and metastasis of osteosarcoma cells by blocking the PI3K/Akt/mTOR signaling pathway.
In conclusion, we provided evidence that GPNMB silencing regulated the proliferation and metastasis of osteosarcoma cells by suppressing the PI3K/Akt/mTOR signaling pathway. Thus, GPNMB may be a potential therapeutic target for osteosarcoma treatment. PMID: 29620278 [PubMed - as supplied by publisher]
Source: Oncology Reports - April 6, 2018 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Long non-coding RNA THOR promotes human osteosarcoma cell growth in vitro and in vivo.
Abstract Long non-coding RNA (LncRNA) dysregulation is associated with human osteosarcoma (OS) cell progression. Recent studies have characterized a novel but ultra-conserved LncRNA THOR ("Lnc-THOR") as a cancer-specific LncRNA, mediating cell growth. In the current study, we show that Lnc-THOR is expressed in established and primary human OS cells. It is also detected in human OS tissues, but not in the surrounding normal bone tissues. siRNA-induced knockdown or CRSIPR/Cas9-mediated knockout Lnc-THOR significantly inhibited human OS cell survival and proliferation. Insulin-like growth factor 2 mRNA-binding protei...
Source: Biochemical and Biophysical Research communications - April 4, 2018 Category: Biochemistry Authors: Chen W, Chen M, Xu Y, Chen X, Zhou P, Zhao X, Pang F, Liang W Tags: Biochem Biophys Res Commun Source Type: research